| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Zavitsanou, X F Huan. Decreased [(3)H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. Neuroscience. vol 109. issue 4. 2002-05-23. PMID:11927153. |
competition experiments were performed in order to examine the pharmacological profile of [(3)h]spiperone binding, and revealed that: (i) displacement of [(3)h]spiperone binding by clozapine and mianserin was significantly reduced in the schizophrenia group as compared to the control group (-26% and -16% respectively); (ii) the order of displacement potency of the drugs tested was: haloperidol>mianserin>butaclamol approximately risperidone>clozapine>2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene. |
2002-05-23 |
2023-08-12 |
Not clear |
| C J Hong, Y W Yu, C H Lin, C Y Cheng, S J Tsa. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatric genetics. vol 11. issue 4. 2002-05-17. PMID:11807413. |
association analysis for nmda receptor subunit 2b (grin2b) genetic variants and psychopathology and clozapine response in schizophrenia. |
2002-05-17 |
2023-08-12 |
Not clear |
| C J Hong, Y W Yu, C H Lin, C Y Cheng, S J Tsa. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatric genetics. vol 11. issue 4. 2002-05-17. PMID:11807413. |
it has also been demonstrated that the level of an ionotropic n-methyl-d-aspartate 2b subunit (grin2b) of the glutamate receptor tends to increase after subchronic administration of clozapine, suggesting that grin2b may play an active role in the pathogenesis of schizophrenia and the function of clozapine medication. |
2002-05-17 |
2023-08-12 |
Not clear |
| V Ozdemir, W Kalow, A B Okey, M S Lam, L J Albers, C Reist, J Fourie, P Posner, E J Collins, R Ro. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Journal of clinical psychopharmacology. vol 21. issue 6. 2002-05-07. PMID:11763009. |
antipsychotic response to clozapine varies markedly among patients with schizophrenia. |
2002-05-07 |
2023-08-12 |
Not clear |
| Sudabeh Shirazi-Southall, Dana Ellen Rodriguez, George G Nomiko. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 26. issue 5. 2002-05-07. PMID:11927183. |
thus, olanzapine and clozapine increased ach to a greater extent than other tested antipsychotics, explaining perhaps their purported beneficial effect in cognitive function in schizophrenia. |
2002-05-07 |
2023-08-12 |
rat |
| G Saba, G Dumortier, K Kalalou, R Benadhira, K Degrassat, J Glikman, D Janue. Lamotrigine--clozapine combination in refractory schizophrenia: three cases. The Journal of neuropsychiatry and clinical neurosciences. vol 14. issue 1. 2002-05-02. PMID:11884664. |
lamotrigine--clozapine combination in refractory schizophrenia: three cases. |
2002-05-02 |
2023-08-12 |
Not clear |
| Pierre-Michel Llorca, Christophe Lancon, Béatrice Disdier, Jean Farisse, Christophe Sapin, Pascal Auquie. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. Journal of psychiatry & neuroscience : JPN. vol 27. issue 1. 2002-04-09. PMID:11836974. |
effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. |
2002-04-09 |
2023-08-12 |
Not clear |
| Pierre-Michel Llorca, Christophe Lancon, Béatrice Disdier, Jean Farisse, Christophe Sapin, Pascal Auquie. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. Journal of psychiatry & neuroscience : JPN. vol 27. issue 1. 2002-04-09. PMID:11836974. |
to assess the relation between plasma concentrations of clozapine and its 2 main metabolites desmethyl clozapine and clozapine n-oxide, and clinical change in a sample of inpatients with schizophrenia who were resistant to conventional neuroleptics. |
2002-04-09 |
2023-08-12 |
Not clear |
| E Lindström, T Lewander, U Malm, U F Malt, H Lublin, U G Ahlfor. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nordic journal of psychiatry. vol 55 Suppl 44. 2002-04-04. PMID:11860666. |
the patient sample consisted of 63 patients with schizophrenia under maintenance treatment with risperidone, clozapine or classical antipsychotics. |
2002-04-04 |
2023-08-12 |
Not clear |
| R Mofsen, J Balte. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clinical therapeutics. vol 23. issue 10. 2002-04-03. PMID:11726006. |
although the efficacy of clozapine in the management of treatment-resistant schizophrenia has been well established, reports of relapse after conversion to a generic formulation are becoming more common. |
2002-04-03 |
2023-08-12 |
Not clear |
| L Chalasani, R Kant, K N Chengapp. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 46. issue 10. 2002-03-20. PMID:11816319. |
clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. |
2002-03-20 |
2023-08-12 |
Not clear |
| L Chalasani, R Kant, K N Chengapp. Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 46. issue 10. 2002-03-20. PMID:11816319. |
to evaluate the impact of clozapine on aggressive behaviour and clinical outcomes in children and adolescents with schizophrenia or schizoaffective disorder. |
2002-03-20 |
2023-08-12 |
Not clear |
| David C Henderso. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS drugs. vol 16. issue 2. 2002-03-19. PMID:11825099. |
while definitive studies have yet to be reported, mounting evidence suggests that the atypical antipsychotic agents, particularly clozapine and olanzapine, may significantly impair glucose metabolism and increase the risk of diabetes in patients with schizophrenia. |
2002-03-19 |
2023-08-12 |
Not clear |
| V C Kirpekar, S M Deshpande, P P Josh. Reversible myocarditis in a patient receiving clozapine. Indian heart journal. vol 53. issue 6. 2002-03-14. PMID:11838936. |
we report the case of a 2 6-year-old patient who developed reversible myocarditis during treatment with clozapine for chronic resistant schizophrenia. |
2002-03-14 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, M G Scordo, M Ancione, A Madia, A Levit. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Therapeutic drug monitoring. vol 23. issue 6. 2002-03-07. PMID:11802103. |
the effect of reboxetine on steady-state plasma concentrations of the atypical antipsychotics clozapine and risperidone was studied in 14 patients with schizophrenia or schizoaffective disorder with associated depressive symptoms. |
2002-03-07 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| Jan Volavka, Pal Czobor, Brian Sheitman, Jean-Pierre Lindenmayer, Leslie Citrome, Joseph P McEvoy, Thomas B Cooper, Miranda Chakos, Jeffrey A Lieberma. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823268. |
the authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder. |
2002-03-06 |
2023-08-12 |
Not clear |
| Theodore T Kolivakis, Howard C Margolese, Linda Beauclair, Guy Chouinar. Clozapine for first-episode schizophrenia. The American journal of psychiatry. vol 159. issue 2. 2002-03-06. PMID:11823283. |
clozapine for first-episode schizophrenia. |
2002-03-06 |
2023-08-12 |
Not clear |
| P I Oh, M Iskedjian, A Addis, K Lanctôt, T R Einarso. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 8. issue 4. 2002-02-28. PMID:11743592. |
pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. |
2002-02-28 |
2023-08-12 |
Not clear |
| P I Oh, M Iskedjian, A Addis, K Lanctôt, T R Einarso. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 8. issue 4. 2002-02-28. PMID:11743592. |
clozapine appears to be a very cost effective therapy in patients with treatment-resistant schizophrenia compared with haloperidol and chlorpromazine. |
2002-02-28 |
2023-08-12 |
Not clear |